Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
3.190
-0.030 (-0.93%)
Jun 20, 2025, 11:46 AM - Market open
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
186.91M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
OMER News
- 9 days ago - Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga
- 23 days ago - Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster - Seeking Alpha
- 24 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
- 5 weeks ago - Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 5 weeks ago - Omeros Corporation Reports First Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 - Business Wire
- 5 weeks ago - Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 - Business Wire
- 6 weeks ago - FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date - Business Wire